Deals > All

East Germany North Germany South Germany West Germany Austria Germany Switzerland [ # 12 & 35 ]

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3757 | Ordered by Date (descending)
1 2 3 ... 27 28 29 ... 36 37 38

Deal: Collaboration or Financing	Date
Intelligent Pharma–Mind the Byte: investment, 201801 acquisition €na 100% of Intelligent Pharma by Mind the Byte	2018-01-11
Mind the Byte–SEVERAL: investment, 201801– financing round €3m (1/3 of company) to finance acquisition of Intelligent Pharma PLANNED	2018-01-11
Structural Genomics Consortium–Enamine: chemical compound libraries, 201801– supply new generation of Diamond-SGC-iNEXT (DSI) Poised Library	2018-01-10
BeiGene–Boehringer: biopharmaceuticals, 201801– supply manufacturing of tislelizumab by Boehringer in Shanghai	2018-01-09
BioNTech–Scancell: cancer immunotherapy, 201801– collab research using Moditope platform w excl license option for BioNTech	2018-01-09
General Electric–Roche: diagnostics, 201801– collab developm integrated digital + IVD + in vivo diagnostics platform for oncology + critical care	2018-01-08
Indivumed–EU (govt): credit, 201801– EIB/EFSI loan €40m to create Global Cancer Database Solution	2018-01-08
TiGenix–Takeda: investment, 201801– aquisition public cash takeover offer €520m for remaining 95.8% for €1.78/share	2018-01-05
BioNTech–Fidelity: investment, 201801 financing round Series A totalling $270m incl new + co-investor Fidelity Management & Research	2018-01-04
BioNTech–Invus Group: investment, 201801 financing round Series A totalling $270m incl new + co-investor Invus	2018-01-04
BioNTech–Janus Henderson: investment, 201801 financing round Series A totalling $270m incl new + co-investor Janus Henderson Investors	2018-01-04
BioNTech–Redmile Group: investment, 201801 financing round Series A totalling $270m incl new + lead investor Redmile Group LLC	2018-01-04
BioNTech–SEVERAL: investment, 201801 financing round Series A $270m led by new investor Redmile Group LLC	2018-01-04
BioNTech–Strüngmann Group: investment, 201801 financing round Series A totalling $270m incl returning co-investor Strüngmann Family Office	2018-01-04
CureVac–Arcturus Therapeutics: mRNA therapeutics, 201801– strategic collab for lipid-mediated mRNA drugs using RNAoptimizer + LUNAR system	2018-01-04
CureVac–BMC Communications: public relations, 201801 service existent by BMC	2018-01-04
Enterome–BPCE: investment, 201801 financing round Series D totalling €32m incl existing investor Seventure + Health for Life Capital	2018-01-04
Enterome–Lundbeck: investment, 201801 financing round Series D totalling €32m incl existing investor LundbeckFonden Ventures	2018-01-04
Enterome–Nestlé: investment, 201801 financing round Series D totalling €32m incl existing investor Nestlé Health Science	2018-01-04
Enterome–SEVERAL: investment, 201801 financing round Series D €32m incl Seventure + Health for Life Capital + Lundbeck Fonden + Omnes Capital et al	2018-01-04
Miracor–SEVERAL: investment, 201801 financing round Series D €25m incl equity + debt + cash advance grant from Walloon govt	2018-01-04
Oculis–Bay City Capital: investment, 201801 financing round Series B totalling CHF20m incl new + co-lead investor Bay City Capital	2018-01-04
Oculis–Brunnur Ventures: investment, 201801 financing round Series B totalling CHF20m incl existing + co-investor Brunnur Ventures	2018-01-04
Oculis–Huntsworth: public relations, 201801 service existent by Citigate Dewe Rogerson	2018-01-04
Oculis–Nan Fung: investment, 201801 financing round Series B totalling CHF20m incl new + co-lead investor Pivotal BioVenture Partners	2018-01-04
Oculis–Novartis: investment, 201801 financing round Series B totalling CHF20m incl new + co-lead investor Novartis Venture Fund	2018-01-04
Oculis–SEVERAL: investment, 201801 financing round Series B CHF20m led by Bay City Capital + NVF + Pivotal BioVenture Partners	2018-01-04
Oculis–Silfurberg: investment, 201801 financing round Series B totalling CHF20m incl existing + co-investor Silfurberg	2018-01-04
Rewind Therapeutics–Boehringer: investment, 201801 financing round Series A totalling €15.2m incl co-lead investor BIVF	2018-01-04
Rewind Therapeutics–Flanders (govt): investment, 201801 financing round Series A totalling €15.2m incl co-lead investor PMV	2018-01-04
Rewind Therapeutics–Merck (DE): investment, 201801 financing round Series A totalling €15.2m incl co-lead investor Merck Ventures	2018-01-04
Rewind Therapeutics–SEVERAL: investment, 201801 financing round Series A €15.2m led by BIVF + Merck Ventures + PMV	2018-01-04
Rewind Therapeutics–Univ Leuven: investment, 201801 financing round Series A totalling €15.2m incl co-investors KU Leuven CD3 + KU Leuven GFF	2018-01-04
Themis Bioscience–SEVERAL: investment, 201801 financing round Series C €10m led by new investor GHIF	2018-01-04
Themis Bioscience–Trophic Communications: public relations, 201801 service existent by Trophic	2018-01-04
BASF–Biocrates: investment, 201801 acquisition of Metanomics Health GmbH by Biocrates from BASF Plant Science GmbH	2018-01-03
Biocrates–BASF: investment, 201801 financing round incl BASF Plant Science GmbH + MIG Fonds + GA Asset Fund	2018-01-03
Biocrates–MIG Fonds: investment, 201801 financing round incl BASF Plant Science GmbH + MIG Fonds + GA Asset Fund	2018-01-03
Biocrates–SEVERAL: investment, 201801 financing round incl BASF Plant Science GmbH + MIG Fonds + GA Asset Fund	2018-01-03
Biocrates–Xolaris Service KVG: investment, 201801 financing round incl BASF Plant Science GmbH + MIG Fonds + GA Asset Fund	2018-01-03
Centogene–MacDougall Biomedical Communications: public relations, 201801 service existent by MacDougall	2018-01-03
CRISPR Therapeutics–SEVERAL: investment, 201801 public offering $113.75m of 5m+750k common shares at $22.75/share	2018-01-03
Indivior–Addex: ADX71441, 201801– license + collab agreem $5m upfront + $4m research funding + $330m milestones plus royalties	2018-01-03
Central BioHub–in.vent Diagnostica: in vitro diagnostics, 201801 collab existent	2018-01-02
Clariant–Global Bioenergies: biopolymers, –201801 collab developm bio-based polymers for cosmetics developed w sugar-based isobutene	2018-01-02
Aquila Biolabs–Germany (govt): investment, 2018 financing round pre-Series A totalling 7-digit € incl investor KfW Bankengruppe	2018-01-01
Aquila Biolabs–PERSON: investment, 2018 financing round pre-Series A totalling 7-digit € incl investor Jürgen Schumacher	2018-01-01
Aquila Biolabs–PERSON: investment, 2018 financing round pre-Series A totalling 7-digit € incl investor Robert Huber	2018-01-01
Aquila Biolabs–Seed Fonds Aachen: investment, 2018 financing round pre-Series A totalling 7-digit € incl investor Seed Fonds Aachen II	2018-01-01
Aquila Biolabs–SEVERAL: investment, 2018 financing round pre-Series A 7-digit € from Seed Fonds Aachen II + KfW + J Schumacher + R Huber	2018-01-01
Century Therapeutics–Fujifilm: iPSC technnology, 2018– collab developm iPSC-derived immune effector cells for cancer + license + supply by FDCI	2018-01-01
CRISPR Therapeutics–ViaCyte: regenerative medicine, 2018– collab incl gene-edited allogeneic stem cell-derived therapies for type 1 diabetes	2018-01-01
Dopavision–Germany (govt): grant, 2018– BMBF grant €1.4m over 3 years	2018-01-01
European Pharma Oligonucleotide Consortium–AstraZeneca: oligonucleotide drugs, 2018– collab AstraZeneca is founding member of EPOC	2018-01-01
European Pharma Oligonucleotide Consortium–Biogen: oligonucleotide drugs, 2018– collab Biogen is founding member of EPOC	2018-01-01
European Pharma Oligonucleotide Consortium–GSK: oligonucleotide drugs, 2018– collab GSK is founding member of EPOC	2018-01-01
European Pharma Oligonucleotide Consortium–JnJ: oligonucleotide drugs, 2018– collab Janssen is founding member of EPOC	2018-01-01
European Pharma Oligonucleotide Consortium–Pfizer: oligonucleotide drugs, 2018– collab Pfizer is founding member of EPOC	2018-01-01
European Pharma Oligonucleotide Consortium–Roche: oligonucleotide drugs, 2018– collab Roche is founding member of EPOC	2018-01-01
European Pharma Oligonucleotide Consortium–Sanofi: oligonucleotide drugs, 2018– collab Sanofi is founding member of EPOC	2018-01-01
Exum Instruments–Elemental Scientific: Massbox, 2018– TOFwerk + ESI join as equity partners to design + produce first instrument	2018-01-01
Exum Instruments–TOFwerk: investment, 2018 TOFwerk + ESI join as equity partners to design + produce first instrument	2018-01-01
Exum Instruments–TOFwerk: Massbox, 2018– TOFwerk + ESI join as equity partners to design + produce first instrument	2018-01-01
MedXCell–SEVERAL: investment, 2018 seed financing round CHF1.5m	2018-01-01
Pfizer–BioNTech: mRNA-based vaccines, 2018– collab development of influenza vaccines	2018-01-01
Siemens–OTHER: investment, 2018H1 PLANNED listing of newSiemens Healthineers AG at Frankfurt Stock Exchange	2018-01-01
BioNTech–ICR: public relations, 201712 service existent by ICR Healthcare in US	2017-12-21
Ignyta–Roche: investment, 201712– cash tender offer $1.7b for all outstanding shares at $27/share	2017-12-21
Roche–Idorsia: cancer immunotherapy, 201712– collab research + excl license option €15m upfront + €445m milestones plus sales milestones + royalties	2017-12-20
Roche–DiCE Molecules: small-molecule drug discovery, 201712– multi-year research collab €na using DiCE technology with Genentech	2017-12-19
Boehringer–Autifony: CNS drugs, 201712–202008 collab €25m upfront + €627.5m milestones excl option to KV3.1/3.2 modulators for BI TERMINATED 8/20	2017-12-18
Danaher–Cotecna: mass spectrometry, –201712 collab developm LC-MS/MS method for pesticide detection by Sciex + NofaLab	2017-12-18
Hadean Ventures–SEVERAL: investment, 201712 closing €100m of Hadean Capital I fund incl investors Argentum + Saminvest et al.	2017-12-18
Roche–Horizon Discovery: reference standards, 201712– collab developm + supply of FFPE reference standards for ICH-NTRK assays for Roche Dx	2017-12-18
Fast Track Diagnostics–Siemens: investment, 201712 acquisiton €na of FTD by Siemens Healthineers	2017-12-15
Evotec–TU Dresden: drug discovery, 201712– collab research €na small-molecule candidates for retinal diseases using iPSC technology with CRTD	2017-12-13
Flexion Therapeutics–GeneQuine: gene therapy, 201712 acquisition $2m upfront + $62.7m milestones + royalties ww rights to GQ-203 by Flexion	2017-12-13
NorthSea Therapeutics–BASF: icosabutate, 201712– license from Pronova BioPharma Norge AS	2017-12-12
NorthSea Therapeutics–SEVERAL: investment, 201712 financing round Series A €25m co-led by Forbion + BGV + incl Novo Seeds + New Science Ventures	2017-12-12
Oncgnostics–SEVERAL: investment, 201712–201801 crowdfunding campaign €750k via Seedmatch platform	2017-12-12
AbeXXa Biologics–Boehringer: investment, 201712 existent investment by BIVF	2017-12-11
Aelin Therapeutics–Boehringer: investment, 201712 financing round Series A totalling €27m incl investor BIVF	2017-12-11
Aelin Therapeutics–Flanders (govt): investment, 201712 financing round Series A totalling €27m incl investor PMV	2017-12-11
Aelin Therapeutics–Fund+: investment, 201712 financing round Series A totalling €27m incl investor Fund+	2017-12-11
Aelin Therapeutics–Life Sciences Partners: investment, 201712 financing round Series A totalling €27m incl lead investor LSP	2017-12-11
Aelin Therapeutics–Novartis: investment, 201712 financing round Series A totalling €27m incl investor Novartis Venture Fund	2017-12-11
Aelin Therapeutics–SEVERAL: investment, 201712 financing round Series A €27m from LSP + PMV + Novartis Venture Fund + BIVF + Fund+	2017-12-11
Boehringer–AbeXXa Biologics: drug target research, 201712 collab existent to identify molecular protein targets for cancer	2017-12-11
Boehringer–Univ California: cancer vaccine, 201712 collab existent to develop vaccine technology platform with UCLA	2017-12-11
Hookipa–BioMedPartners: investment, 201712 financing round Series C totalling €50m incl returning investor BioMedPartners	2017-12-11
Hookipa–Boehringer: investment, 201712 financing round Series C totalling €50m incl returning investor BIVF	2017-12-11
Hookipa–Forbion: investment, 201712 financing round Series C totalling €50m incl returning investor Forbion Capital Partners	2017-12-11
Hookipa–Gilead: investment, 201712 financing round Series C totalling €50m incl new + strategic investor Gilead	2017-12-11
Hookipa–HBM: investment, 201712 financing round Series C totalling €50m incl new investor HBM Partners	2017-12-11
Hookipa–Hillhouse Capital: investment, 201712 financing round Series C totalling €50m incl new investor Hillhouse Capital	2017-12-11
Hookipa–OTHER: investment, 201712 financing round Series C totalling €50m incl undisclosed US public investment fund as new + lead investor	2017-12-11
Hookipa–SEVERAL: investment, 201712 financing round Series C €50m led by undisclosed US public investment fund	2017-12-11
Hookipa–Sirona Capital: investment, 201712 financing round Series C totalling €50m incl new investor Sirona Capital	2017-12-11
Hookipa–Sofinnova: investment, 201712 financing round Series C totalling €50m incl returning investor Sofinnova Partners	2017-12-11
Hookipa–Takeda: investment, 201712 financing round Series C totalling €50m incl returning investor Takeda Ventures	2017-12-11

1 2 3 ... 27 28 29 ... 36 37 38

Picture [iito] No Content Marketing 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)